<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="51945">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01881230</url>
  </required_header>
  <id_info>
    <org_study_id>ABI-007-MBC-001</org_study_id>
    <secondary_id>2013-000113-20</secondary_id>
    <nct_id>NCT01881230</nct_id>
  </id_info>
  <brief_title>Evaluate Risk/Benefit of Nab Paclitaxel in Combinaton With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer</brief_title>
  <acronym>tnAcity</acronym>
  <official_title>A Phase 2/3, Multi-Center, Open-Label, Randomized Study of Weekly Nab®-Paclitaxel in Combination With Gemcitabine or Carboplatin, Compared to Gemcitabine/Carboplatin, as First Line Treatment in Subjects With ER, PgR, and HER2 Negative (Triple Negative) Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celgene Corporation</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Argentina: Ministry of Health</authority>
    <authority>Australia: Department of Health and Ageing Therapeutic Goods Administration</authority>
    <authority>Austria: Agency for Health and Food Safety</authority>
    <authority>Brazil: Ministry of Health</authority>
    <authority>Canada: Health Canada</authority>
    <authority>Finland: Finnish Medicines Agency</authority>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <authority>Greece: National Organization of Medicines</authority>
    <authority>Italy: The Italian Medicines Agency</authority>
    <authority>Japan: Pharmaceuticals and Medical Devices Agency</authority>
    <authority>Portugal: National Pharmacy and Medicines Institute</authority>
    <authority>Spain: Spanish Agency of Medicines</authority>
    <authority>Sweden: Medical Products Agency</authority>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the safety and efficacy of nab-paclitaxel in
      combination with either gemcitabine or carboplatin to the combination of gemcitabine and
      carboplatin as first line treatment in female subjects with triple negative metastatic
      breast cancer (TNMBC).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      ABI-007-MBC- 001 is a Phase 2/3, multicenter, open-label, randomized, study that will
      compare the safety and efficacy of weekly nab-paclitaxel in combination with either
      gemcitabine or carboplatin to the combination of gemcitabine and carboplatin as first line
      therapy in female subjects with Estrogen Receptor (ER), Progesterone Receptor (PgR), and
      human epidermal growth factor receptor 2  (HER2) negative (triple negative) metastatic
      breast cancer (TNMBC). In the phase 2 portion of the study, the combinations of
      nab-paclitaxel plus gemcitabine and nab-paclitaxel plus carboplatin will be evaluated, and a
      comparator arm of gemcitabine combined with carboplatin will be used. In the phase 3 portion
      of the study, the selected nab-paclitaxel combination treatment will be compared to
      gemcitabine combined with carboplatin to evaluate progression free survival, safety and
      tolerability, overall survival, disease control rate and duration of response in triple
      negative metastatic breast cancer (TNMBC) subjects.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">April 2016</completion_date>
  <primary_completion_date type="Anticipated">October 2015</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Progression Free Survival (PFS) for triple negative metastatic breast cancer subjects  (Phase 2)</measure>
    <time_frame>Up to approximately 18 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>time from the randomization date to the start of disease progression or subject death from any cause (progression assessed by investigator using Response Evaluation Criteria in Solid Tumors 1.1  (RECIST 1.1 guidelines) for triple negative metastatic breast cancer (TNMBC) subjects</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression Free Survival (PFS) for triple negative metastatic breast cancer subjects  (Phase 3)</measure>
    <time_frame>Up to approximately 46 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Time from the randomization date to the start of disease progression or subject death from any cause (assessment based on an independent blinded radiologist(s) evaluation using RECIST 1.1 guidelines  for triple negative metastatic breast cancer (TNMBC) subjects</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Investigator-determined Overall Response Rate (ORR) for triple negative metastatic breast cancer subjects (Phase 2)</measure>
    <time_frame>Up to approximately 18 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Complete response (CR) or partial response (PR) based on investigator assessment of response using RECIST 1.1 guidelines</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of triple negative metastatic breast cancer  subjects who initiated Cycle 6 (Phase 2)</measure>
    <time_frame>Up to approximately 18 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Defined as the Percentage of subjects who initiated Cycle 6 of treatment regardless of the need for dose modifications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator determined Overall Survival (OS) for triple negative metastatic breast cancer (TNMBC) subjects  (Phase 2)</measure>
    <time_frame>Up to approximately 18 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Defined as the time between randomization and death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety for triple negative metastatic breast cancer (TNMBC) subjects (Phase 2)</measure>
    <time_frame>up to approximately 19 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Incidence/Grade of Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), laboratory abnormalities; Incidence of subjects experiencing dose modifications (dose interruptions and reductions); Percentage and number of subjects who discontinued for adverse event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Independent blinded radiologists-determined Overall Response Rate (ORR) for triple negative metastatic breast cancer (TNMBC) subjects  (Phase 3)</measure>
    <time_frame>Up to approximately 46 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Confirmed complete or partial response according to RECIST 1.1 guidelines determined by independent, blinded radiologist(s)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) for triple negative metastatic breast cancer (TNMBC) subjects  (Phase 3)</measure>
    <time_frame>Up to approximately 66 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Time between randomization and death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare disease control rate for triple negative metastatic breast cancer (TNMBC) subjects (Phase 3)</measure>
    <time_frame>Up to approximately 46 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Complete response (CR), Partial response (PR), and Stable Disease (SD) more than or equal to 16 weeks for triple negative metastatic breast cancer (TNMBC) subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response for triple negative metastatic breast cancer (TNMBC) subjects  (Phase 3)</measure>
    <time_frame>Up to approximately 46 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>period from confirmed complete or partial response (whichever is first recorded) until the first date that progression free survival event is documented</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of each treatment regimen for triple negative metastatic breast cancer (TNMBC) subjects  (Phase 3)</measure>
    <time_frame>Up to approximately 47 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>: Assessment based on Adverse Events (AEs) , Serious Adverse Events (SAEs), laboratory abnormalities in triple negative metastatic breast cancer (TNMBC) subjects .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator assessed Progression Free Survival (PFS)for  triple negative metastatic breast cancer (TNMBC) subjects  (Phase 3)</measure>
    <time_frame>up to approximately 46 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assessment based on investigator evaluation using RECIST 1.1 guidelines</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">790</enrollment>
  <condition>Breast Tumor</condition>
  <condition>Breast Cancer</condition>
  <condition>Cancer of the Breast</condition>
  <condition>Estrogen Receptor- Negative Breast Cancer</condition>
  <condition>HER2- Negative Breast Cancer</condition>
  <condition>Progesterone Receptor- Negative Breast Cancer</condition>
  <condition>Recurrent Breast Cancer</condition>
  <condition>Stage IV Breast Cancer</condition>
  <condition>Triple-negative Breast Cancer</condition>
  <condition>Triple-negative Metastatic Breast Cancer</condition>
  <condition>Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>nab-Paclitaxel 125mg/m2 plus gemcitabine 1000mg/m2 in TNMBC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment Arm A: nab-Paclitaxel 125mg/m2 on Days 1 and 8 by IV administration over 30 minutes, followed by gemcitabine 1000 mg/m2 on Days 1 and 8 by IV administration over 30 minutes in triple negative metastatic breast cancer (TNMBC) subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>nab-Paclitaxel 125mg/m2 plus carboplatin AUC2 in TNMBC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment Arm B: nab-Paclitaxel 125 mg/m2 on Days 1 and 8 by IV administration over 30 minutes followed by carboplatin AUC 2 on Days 1 and 8 by IV administration over 60 minutes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gemcitabine 1000mg/m2 plus carboplatin AUC2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment Arm C: Gemcitabine 1000 mg/m2 on Days 1 and 8 by IV administration over 30 minutes, followed by carboplatin AUC2 on Days 1 and 8 by IV administration over 60 minutes in triple negative metastatic breast cancer (TNMBC) subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Selected nab Paclitaxel arm from Phase 2 inTNMBC subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 3 Treatment Arm 1: Selected Phase 2 nab paclitaxel treatment arm of either nab-Paclitaxel 125 mg/m2 on Days 1 and 8 by IV administration over 30 minutes  followed by gemcitabine 1000 mg/m2 on Days 1 and 8 by IV administration over 30 minutes OR  nab-Paclitaxel 125 mg/m2 on Days 1 and 8 by IV administration over 30 minutes followed by carboplatin AUC 2 on Days 1 and 8 by IV administration over 60 minutes in triple negative metastatic breast cancer (TNMBC) subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 3: Gemcitabine plus carboplatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Phase 3 Treatment Arm 2: Gemcitabine 1000 mg/m2 on Days 1 and 8 by IV administration over 30 minutes, followed by carboplatin AUC2 on Days 1 and 8 by IV administration over 60 minutes in triple negative metastatic breast cancer (TNMBC) subjects</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nab-Paclitaxel 125 mg/m2 plus carboplatin AUC 2 in triple negative metastatic breast cancer (TNMBC) subjects</intervention_name>
    <arm_group_label>nab-Paclitaxel 125mg/m2 plus carboplatin AUC2 in TNMBC</arm_group_label>
    <other_name>Abraxane</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin AUC 2</intervention_name>
    <arm_group_label>nab-Paclitaxel 125mg/m2 plus carboplatin AUC2 in TNMBC</arm_group_label>
    <arm_group_label>Gemcitabine 1000mg/m2 plus carboplatin AUC2</arm_group_label>
    <arm_group_label>Selected nab Paclitaxel arm from Phase 2 inTNMBC subjects</arm_group_label>
    <arm_group_label>Phase 3: Gemcitabine plus carboplatin</arm_group_label>
    <other_name>Paraplatin,</other_name>
    <other_name>Paraplatin AQ</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine 1000 mg</intervention_name>
    <arm_group_label>nab-Paclitaxel 125mg/m2 plus gemcitabine 1000mg/m2 in TNMBC</arm_group_label>
    <arm_group_label>Gemcitabine 1000mg/m2 plus carboplatin AUC2</arm_group_label>
    <arm_group_label>Selected nab Paclitaxel arm from Phase 2 inTNMBC subjects</arm_group_label>
    <arm_group_label>Phase 3: Gemcitabine plus carboplatin</arm_group_label>
    <other_name>Gemzar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. Female subjects with triple negative metastatic breast cancer, age  18 years or
             older at the time informed consent is signed 2. Pathologically confirmed metastatic
             adenocarcinoma of the breast

             a. Paraffin fixed primary or metastatic site tumor sample (most recently obtained) is
             required for central laboratory biomarker evaluation 3. Pathologically confirmed as
             triple negative, source documented, defined as both of the following

             a. Estrogen Receptor (ER) and Progesterone Receptor (PgR) negative: &lt; 1% of tumor
             cell nuclei are immunoreactive in the presence of evidence that the sample can
             express ER or PgR (positive intrinsic controls) (Hammond, 2010) b. Human Epidermal
             Growth Factor Receptor 2(HER2) negative (Wolff, 2007): i. Immunohistochemistry (IHC)
             0 or 1+, or ii. IHC 2+ and confirmed negative by Fluorescence In Situ Hybridization
             (FISH), (FISH HER2/CEP17 ratio &lt; 1.8), or iii. Average HER2 gene copy number of &lt; 4
             signals/nucleus for test systems without and internal control probe 4. Subjects must
             have received prior adjuvant or neoadjuvant anthracycline therapy; or anthracycline
             treatment must be clinically contraindicated.

             5. Subjects with measurable disease, defined by Response Evaluation Criteria in Solid
             Tumors 1.1 (RECIST 1.1) guidelines 6. No prior cytotoxic chemotherapy for metastatic
             breast cancer. Prior immunotherapy and/or monoclonal antibody therapy are acceptable.
             Prior treatments must have been discontinued at least 30 days prior to start of study
             treatment and all related toxicities must have resolved to Grade 1 or less.

             7. Prior neoadjuvant or adjuvant chemotherapy, if given, must have been completed at
             least 30 days before start of study treatment with all related toxicities resolved,
             and documented evidence of disease progression per RECIST 1.1 guidelines is required
             8. Prior radiotherapy must have completed at least 2 weeks before randomization, with
             full recovery. The measurable disease (target lesions) must be completely outside the
             radiation portal or there must be unequivocal radiologic or clinical exam proof of
             progressive disease within the radiation portal 9. At least 30 days from major
             surgery before the start of study treatment, with full recovery 10. Eastern
             Cooperative Oncology Group (ECOG) performance status 0-1 11. Subject has the
             following blood counts at screening:

               -  Absolute Neutrophil Count (ANC) ≥ 1500/mm2 ;

               -  platelets ≥ 100,000/mm2 ;

               -  Hemoglobin (Hgb) ≥ 9 g/dL 12. Subject has the following blood chemistry levels
                  at screening:

               -  aspartate aminotransferase (AST) Serum glutamic-oxaloacetic transaminase (SGOT),
                  Alanine Aminotransferase (ALT ) Serum Glutamic Pyruvate Transaminase (SGPT) ≤
                  2.5 x upper limit of normal range (ULN); if  hepatic metastases present ≤ 5.0 x
                  ULN

               -  total bilirubin ≤ ULN (subjects with Gilbert's syndrome can have bilirubin of up
                  to 1.5 x ULN)

               -  alkaline phosphatase ≤ 2.5 x ULN (unless bone metastases are present in the
                  absence of liver metastasis)

               -  creatinine clearance &gt; 60 mL/min (by Cockcroft-Gault) 13. Females of
                  child-bearing potential [defined as a sexually mature women who (1) have not
                  undergone hysterectomy (the surgical removal of the uterus) or bilateral
                  oophorectomy (the surgical removal of both ovaries) or (2) have not been
                  naturally postmenopausal for at least 24 consecutive months (i.e., has had
                  menses at any time during the preceding 24 consecutive months)] must:

               -  Agree to the use of two physician-approved contraceptive methods (oral,
                  injectable, or implantable hormonal contraceptive; tubal ligation; intra-uterine
                  device; barrier contraceptive with spermicide; or vasectomized partner) while on
                  study medication; and for 28 days following the last dose of study medication;
                  and

               -  Negative serum pregnancy test result at screening (performed by central lab)
                  confirmed by local negative urine pregnancy dipstick within 72 hours prior to
                  the first dose of IP); pregnancy test with sensitivity of at least 25 mIU/mL 14.
                  Females must abstain from breastfeeding during study participation and 28 days
                  after investigational product discontinuation 15. Understand and voluntarily
                  sign an informed consent document prior to any study related
                  assessments/procedures are conducted 16. Able to adhere to the study visit
                  schedule and other protocol requirements

        Exclusion Criteria:

          -  A subject will not be eligible for inclusion in this study if any of the following
             criteria apply:

               1. Male subjects with triple negative metastatic breast cancer.

               2. Concurrent chemotherapy or any other anti tumor therapy for breast cancer. Prior
                  immunotherapy &amp; monoclonal antibody therapy are acceptable.

               3. Concurrent or prior anticoagulation therapy within 7 days of first dose of study
                  treatment

               4. History of, or known current evidence of brain metastasis, including
                  leptomeningeal involvement.

               5. Subjects with bone as the only site of metastatic disease

               6. Serious intercurrent medical or psychiatric illness, including serious active
                  infection

               7. History of class II-IV congestive heart failure or myocardial infarction within
                  6 months of beginning study treatment

               8. History of other primary malignancy in the last 5 years. Subjects with prior
                  history of in situ cancer or basal or localized squamous cell skin cancer are
                  eligible. Subjects with other malignancies are eligible if they were cured by
                  surgery alone or surgery plus radiotherapy and have been continuously
                  disease-free for at least 5 years

               9. Subjects with a history of interstitial lung disease, history of slowly
                  progressive dyspnea and unproductive cough, sarcoidosis, silicosis, idiopathic
                  pulmonary fibrosis, pulmonary hypersensitivity pneumonitis or multiple allergies

              10. Peripheral neuropathy Grade ≥ 2 by National Cancer Institute Common Terminology
                  Criteria for Adverse Events (NCI CTCAE) v4.0

              11. Subjects who have received an investigational product within the previous 4
                  weeks prior to study randomization

              12. Subject is currently enrolled, or will enroll in a different clinical study in
                  which investigational therapeutic procedures are performed or investigational
                  therapies are administered while participating in this study

              13. Pregnant or nursing women

              14. Subjects with prior hypersensitivity to nab-paclitaxel, gemcitabine, carboplatin
                  or any other platin, or nucleoside analogue agents

              15. Any significant medical condition, laboratory abnormality, or psychiatric
                  illness that would prevent the subject from participating in the study

              16. Any condition including the presence of laboratory abnormalities, which places
                  the subject at unacceptable risk if she were to participate in the study

              17. Any condition that confounds the ability to interpret data from the study

              18. History of seropositive human immunodeficiency virus (HIV) or subjects who are
                  receiving immunosuppressive or myelosuppressive medications that would, in the
                  opinion of the investigator, increase the risk of serious neutropenic
                  complications

              19. Initiation of bisphosphonate for bone metastasis therapy while on study.
                  Subjects receiving bisphosphonate therapy initiated ≥ 1 day prior to starting
                  investigational product are eligible.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Debora Barton, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Celgene Corporation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Associate Director, Clinical Trial Disclosure</last_name>
    <phone>1-888-260-1599</phone>
    <email>clinicaltrialdisclosure@celgene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Arizona Center for Cancer Care</name>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <zip>83506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>424-208-8866</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ironwood Cancer Center</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85206</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>480-855-2225</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arizona Cancer Research Alliance</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85251</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>424-208-8866</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Scottsdale</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Highlands Oncology Group</name>
      <address>
        <city>Fayetteville</city>
        <state>Arkansas</state>
        <zip>72703</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>479-587-1700</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pacific Cancer Medical Center Inc</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>California Cancer Associates for Research and Excellence</name>
      <address>
        <city>Escondido</city>
        <state>California</state>
        <zip>92025</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>424-208-8866</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>UC San Diego Moores Cancer Center</name>
      <address>
        <city>LaJolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>858-822-5223</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Glendale Adventist Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>424-208-8866</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wilshire Oncology Medical Group</name>
      <address>
        <city>Rancho Cucamonga</city>
        <state>California</state>
        <zip>91750</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>424-208-8866</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Coastal Integrative Cancer Care</name>
      <address>
        <city>San Luis Obispo</city>
        <state>California</state>
        <zip>93401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>424-208-8866</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Central Coast Medical Oncology Corp</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>93454</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>424-208-8866</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Redwood Regional Medical Group Inc.</name>
      <address>
        <city>Santa Rosa</city>
        <state>California</state>
        <zip>95403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>707-521-3830</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Center For Hematology Oncology</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33486</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>561-955-4800</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Cancer Institute</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists North</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>239-274-9930</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Palm Beach Cancer Institute</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>561-366-4100</phone>
      <phone_ext>4757</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>Joliet Oncology-Hematology Associates Ltd.</name>
      <address>
        <city>Joliet</city>
        <state>Illinois</state>
        <zip>60435</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>815-730-3098</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Carle Cancer Center</name>
      <address>
        <city>Urbana</city>
        <state>Illinois</state>
        <zip>61801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Clinical Research of Indiana, LLC</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>317-297-2208</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>410-328-3546</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Center For Cancer and Blood Disorders</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>301-571-2016</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>313-916-2438</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Minnesota Oncology Hematology PA</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>612-863-8716</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Missouri Baptist Medical Center</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63131</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>New Hampshire Oncology Hematology</name>
      <address>
        <city>Concord</city>
        <state>New Hampshire</state>
        <zip>03301</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dartmouth Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Englewood Hospital and Medical Center -Drs. Forte, Schleider, Atlas PA</name>
      <address>
        <city>Englewood</city>
        <state>New Jersey</state>
        <zip>07631</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hematology/Oncology Associates of Central New York</name>
      <address>
        <city>East Syracuse</city>
        <state>New York</state>
        <zip>13057</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alamance Regional Medical Center</name>
      <address>
        <city>Burlington</city>
        <state>North Carolina</state>
        <zip>27215-8700</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>336-538-7197</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>513-584-7698</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oncology Hematology Care</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>877-691-7274</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mark H. Zangmeister Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>614-383-6236</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Toledo Community Oncology Program</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43617</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cancer Centers of Southwest Oklahoma</name>
      <address>
        <city>Lawton</city>
        <state>Oklahoma</state>
        <zip>73505</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>North Bend Medical Center</name>
      <address>
        <city>Coos Bay</city>
        <state>Oregon</state>
        <zip>97420</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>424-208-8866</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Providence Cancer Center Oncology Hematology</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>503-215-2619</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northwest Cancer Specialists, PC</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Mary Medical Center</name>
      <address>
        <city>Langhorne</city>
        <state>Pennsylvania</state>
        <zip>19047</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>215-710-5328</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Magee Women's Hospital</name>
      <address>
        <city>Pittsuburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>412-641-6500</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>South Carolina Oncology Associates PA</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>803-461-3000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Avera Research Institute</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chattanooga Oncology Hematology Associates</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>877-691-7274</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>877-691-7274</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas Oncology, PA</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75702</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>214-346-3508</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas Oncology, PA</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231-4400</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>877-691-7274</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Center For Cancer and Blood Disorders</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>817-759-7000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>UT Physicians General Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>713-704-3179</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas Oncology, PA</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75702</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hematology Oncology Associates of Fredericksburg</name>
      <address>
        <city>Fredericksburg</city>
        <state>Virginia</state>
        <zip>22408</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Institute</name>
      <address>
        <city>Midlothian</city>
        <state>Virginia</state>
        <zip>23114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>877-691-7274</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Institute</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical Oncology Associates</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>509-462-2273</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Edwards Comprehensive Cancer Center</name>
      <address>
        <city>Huntington</city>
        <state>West Virginia</state>
        <zip>25701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Saint Vincent Hospital</name>
      <address>
        <city>Green Bay</city>
        <state>Wisconsin</state>
        <zip>54301</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Columbia Saint Mary's</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>414-298-7267</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Canberra Hospital</name>
      <address>
        <city>Garran</city>
        <state>Australian Capital Territory</state>
        <zip>2605</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Frankston Hospital</name>
      <address>
        <city>Frankston</city>
        <state>Victoria</state>
        <zip>3199</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>+61 3 9784 7290</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Border Medical Oncology</name>
      <address>
        <city>Wodonga</city>
        <state>Victoria</state>
        <zip>3690</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+61 26051 5325</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sir Charles Gairdner Hospital</name>
      <address>
        <city>Nedlands</city>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+61 408818656</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <state>Tirol</state>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+43 512 504-82477</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Salzburger Landeskliniken</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+43 662 4482 2847</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medizinische Universitat Wien</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+43 140400 5459</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro de Oncologia Da Bahia</name>
      <address>
        <city>Salvador</city>
        <state>Bahia</state>
        <zip>41820-021</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>+55 71 3341 4175</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oncoclinic Clinica de Oncologia LTDA</name>
      <address>
        <city>Fortaleza</city>
        <state>Ceará</state>
        <zip>60160-230</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>+55 85 3242 2097</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Liga Paranaense de Combate Ao Cancer</name>
      <address>
        <city>Curitiba</city>
        <state>Paraná</state>
        <zip>81520-060</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>+55 41 3361-5195</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Bruno Born</name>
      <address>
        <city>Lajeado</city>
        <state>Rio Grande do Sul</state>
        <zip>95900-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>+55 51 3714 7500</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Sao Lucas Da Pontificia Universidade Catolica Do Rio Grande Do Sul</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande do Sul</state>
        <zip>90610-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>+55 51 3320 3039</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Associação Hospitalar Moinhos de Vento</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande do Sul</state>
        <zip>90560-030</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>+55 51 3314 3296</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Das Clinicas da Faculdade de Medicina de Ribirao Preto-USP</name>
      <address>
        <city>Ribeirao Preto</city>
        <state>Sao Paulo</state>
        <zip>14048-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>+55 16 3602 2589</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto Ribeirãopretano de Combate Ao Câncer</name>
      <address>
        <city>Ribeirão Preto</city>
        <state>São Paulo</state>
        <zip>14015-130</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>+55 16 3011 0810</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital de Base Da Faculdade de Medicina de São José Do Rio Preto</name>
      <address>
        <city>São José Do Rio Preto</city>
        <state>São Paulo</state>
        <zip>15090-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>+55 17 3201 5054</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fundação Pio XII Hospital de Câncer de Barretos</name>
      <address>
        <city>Barretos</city>
        <state>Săo Paulo</state>
        <zip>14784-400</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>+55 17 3321 6637</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Amaral Carvalho</name>
      <address>
        <city>Jaú</city>
        <state>Săo Paulo</state>
        <zip>17210-080</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>55 14 3602 1397</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>INCA Instituto Nacional Do Câncer</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>20560-120</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>+55 21 3207 3810</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein</name>
      <address>
        <city>São Paulo</city>
        <zip>05651-901</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>+55 11 2151 0723</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sociedade Beneficente de Senhoras Hospital Sirio Libanês</name>
      <address>
        <city>São Paulo</city>
        <zip>01308-050</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>+55 11 3155 3705</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto Brasileiro de Controle Do Câncer IBCC</name>
      <address>
        <city>Săo Paulo</city>
        <zip>03102-002</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>+55 11 3474 4249</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHUM Notre Dame Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L 4M1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Victoria Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3A 1A1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital du Saint Scarement Laboratory</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G1S 4L8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital du Saint Sacrement Laboratory</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G1S 4L8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CSSS de Rimouski Neigette</name>
      <address>
        <city>Rimouski</city>
        <state>Quebec</state>
        <zip>G5L 5T1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Saskatchewan Cancer Agency - Allan Blair Cancer Centre</name>
      <address>
        <city>Regina</city>
        <state>Saskatchewan</state>
        <zip>S4T 1A5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Jean Perrin Centre Régional de Lutte Contre Le Cancer D'auvergne</name>
      <address>
        <city>Clermont-ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>+33 4 73 27 84 54</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <state>Baden-Württemberg</state>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+49 6221 56-37870</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Ulm</name>
      <address>
        <city>Ulm</city>
        <state>Baden-Württemberg</state>
        <zip>89075</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>+49 731 500-58520</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>LMU Klinikum der Universität</name>
      <address>
        <city>München</city>
        <state>Bayern</state>
        <zip>80337</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+49 89 5160-4317</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Agaplesion Markus Krankenhaus</name>
      <address>
        <city>Frankfurt am Main</city>
        <state>Hesse</state>
        <zip>60431</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+49 69 9533 2264</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Krankenanstalt Mutterhaus der Borromäerinnen</name>
      <address>
        <city>Trier</city>
        <state>Rheinland-Pfalz</state>
        <zip>54290</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>+49 651 9472795</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sankt Gertrauden-Krankenhaus</name>
      <address>
        <city>Berlin</city>
        <zip>10713</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>+49 30 8272-29887</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University General Hospital of Patras</name>
      <address>
        <city>Patras</city>
        <state>Achaïa</state>
        <zip>26500</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+302610999791</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Athens Medical School - Regional General Hospital &quot;Alexandra&quot;</name>
      <address>
        <city>Athens</city>
        <state>Attica</state>
        <zip>11528</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+302103381541</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Iaso General Hospital of Athens</name>
      <address>
        <city>Athens</city>
        <state>Attiki</state>
        <zip>15562</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+302106502639</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Metropolitan Hospital</name>
      <address>
        <city>Faliro</city>
        <state>Attiki</state>
        <zip>185-47</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+302104809666</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University General Hospital of Heraklion</name>
      <address>
        <city>Heraklion</city>
        <state>Irakleio</state>
        <zip>71110</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+302810392747</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale Per Lo Studio E La Cura Dei Tumori Fondazione Giovanni Pascale</name>
      <address>
        <city>Napoli</city>
        <state>Campania</state>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>+39 081 5903699</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Federico II</name>
      <address>
        <city>Napoli</city>
        <state>Campania</state>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>+39 0817463660</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arcispedale Santa Maria Nuova</name>
      <address>
        <city>Reggio Emilia</city>
        <state>Emilia-Romagna</state>
        <zip>42100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>+39 0522 296614</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria di Ferrara - Arcispedale Sant' Anna</name>
      <address>
        <city>Cona</city>
        <state>Ferrara</state>
        <zip>44124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>+39 0532 237430</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale Tumori Regina Elena</name>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>00144</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+39 06 52666919</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario A Gemelli</name>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>+39 06 30154979</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario A Gemelli</name>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>+39 0630154844</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Sant'andrea</name>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>00189</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+39 0633775831</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>IRCCS Azienda Ospedaliera Universitaria San Martino Instituto Nazionale Per La Ricerca Sul Cancro</name>
      <address>
        <city>Genova</city>
        <state>Liguria</state>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>+39 010 5600669</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera San Gerardo</name>
      <address>
        <city>Monza</city>
        <state>Lombardia</state>
        <zip>20900</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>+39 039 233 9037</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>IRCCS - Istituo Clinico Humanitas - Humanitas Cancer Center</name>
      <address>
        <city>Rozzano</city>
        <state>Lombardia</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+39 02 82244080</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Presidio Ospedaliero della Misericordia</name>
      <address>
        <city>Grosseto</city>
        <state>Toscana</state>
        <zip>58100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>+39 0564 485286</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Oncologico Veneto - I.R.C.C.S.</name>
      <address>
        <city>Padova</city>
        <state>Veneto</state>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>+39 049 821 5290</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria di Bologna - Policlinico S.Orsola-Malpighi</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>+390516364548</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Ospedali Riuniti Papardo-Piemonte</name>
      <address>
        <city>Messina</city>
        <zip>98158</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>+39 0903996138</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Città della Salute e della Scienza di Torino</name>
      <address>
        <city>Turin</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>+39 011 6334133</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Da Luz</name>
      <address>
        <city>Lisboa</city>
        <zip>1500-650</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>+351 217104400</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar de Lisboa Norte, EPE - Hospital de Santa Maria</name>
      <address>
        <city>Lisbon</city>
        <zip>1649-035</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>+351 21 780 5097</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto Portugues de Oncologia Do Porto Francisco Gentil ipopfg Epe</name>
      <address>
        <city>Porto</city>
        <zip>4200-072</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>+351 225 084 000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Espírito Santo</name>
      <address>
        <city>Évora</city>
        <zip>7000-811</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>+351 266740100</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario de Santiago</name>
      <address>
        <city>Santiago de Compostela</city>
        <state>A Coruña</state>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+34 981 950 511/12</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Miguel Servet</name>
      <address>
        <city>Zaragoza</city>
        <state>Aragón</state>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+34 976 76 55 00 x 3825</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Clinic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <state>Cataluna</state>
        <zip>8036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+34 93 227 54 00</phone>
      <phone_ext>3456</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>Onkologikoa-Kutzaren Institutu Onkologikoa</name>
      <address>
        <city>San Sebastian</city>
        <state>Gipuzkoa</state>
        <zip>20014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+34 943 32 83 15</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall D´Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>8035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>+34 932746000 x 4691</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Reina Sofia</name>
      <address>
        <city>Córdoba</city>
        <zip>14008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+34 957 012 408</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <zip>28009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+34 91 426 93 92</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vírgen Macarena</name>
      <address>
        <city>Sevilla</city>
        <zip>41071</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+34 955 92 65 78</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mount Vernon Hospital</name>
      <address>
        <city>Northwood</city>
        <state>London</state>
        <zip>HA6 2RN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>+44 1923 844308</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal United Hospital</name>
      <address>
        <city>Bath</city>
        <state>Somerset</state>
        <zip>BA1 3NG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+44 1225 824797</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Weston Park Hospital</name>
      <address>
        <city>Sheffield</city>
        <state>Yorkshire</state>
        <zip>S10 2SJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+44 114 226 5208</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute UK</name>
      <address>
        <city>London</city>
        <zip>W1G 6AD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+44 20 3219 5200</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Christie Hospital</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>+44 161 918 7469</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Australia</country>
    <country>Austria</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Italy</country>
    <country>Portugal</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 8, 2014</lastchanged_date>
  <firstreceived_date>June 17, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metastatic Breast Cancer</keyword>
  <keyword>Triple Negative Metastatic Breast Cancer</keyword>
  <keyword>Hormone receptor negative</keyword>
  <keyword>HER2 Negative</keyword>
  <keyword>Abraxane</keyword>
  <keyword>nab-Paclitaxel</keyword>
  <keyword>gemcitabine</keyword>
  <keyword>carboplatin</keyword>
  <keyword>TNMBC</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
